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and bone-resorbing osteoclasts is required for bone
developmentandhomeostasis.Here,we identifyEBF2,
a member of the early B cell factor (EBF) family of tran-
scription factors that is expressed in osteoblast pro-
genitors, as a regulator of osteoclast differentiation.
We find that mice homozygous for a targeted inactiva-
tion of Ebf2 show reduced bone mass and an increase
in the number of osteoclasts. These defects are ac-
companied by a marked downregulation of the osteo-
protegerin (Opg) gene, encoding a RANK decoy recep-
tor. EBF2 binds to sequences in theOpg promoter and
transactivates the Opg promoter in synergy with the
Wnt-responsive LEF1/TCF:b-catenin pathway. Taken




The bones of vertebrates are formed and maintained by
the interplay of different cell types. The bone-forming
osteoblasts, which share a mesenchymal precursor with
chondrocytes, secrete the bone extracellular matrix
(ECM), whereas osteoclasts, which differentiate from he-
matopoietic progenitors of the myelomonocytic cell line-
age, degrade the bone matrix (Karsenty and Wagner,
2002; Teitelbaum and Ross, 2003; Baron, 2004). During
development, bone formation is initiated by the conden-
sation of mesenchymal cells that differentiate along the
chondrocytic pathway to form cartilage, which is subse-
quently replaced by bone, generated by osteoblasts in
a process termed endochondral ossification. Alterna-
tively, condensed mesenchymal cells can differentiate
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Veterinary Medicine, 1210 Vienna, Austria.directly into osteoblasts to form intramembranous skel-
etal elements (de Crombrugghe et al., 2001; Olsen et al.,
2000). The formation and maintenance of bones involves
a fine balance between osteoblasts and osteoclasts,
whereby osteoblasts regulate the differentiation of os-
teoclast precursors into terminally differentiated cells
(Takahashi et al., 1988). Changes in the numbers and/or
activities of osteoblasts and osteoclasts can result in
an increase of bone mass, due to a failure of bone resorp-
tion (osteopetrosis) or increased bone production (os-
teosclerosis), or, alternatively, in a loss of bone mass,
termed osteopenia or osteoporosis (Teitelbaum, 2000).
The communication between osteoblasts and osteo-
clasts is governed by at least two signaling pathways.
The macrophage colony-stimulating factor (M-CSF) is
secreted from osteoblasts and provides a survival signal
to osteoclast precursors and osteoclasts (Lagasse and
Weissman, 1997; Tsurukai et al., 2000; Yoshida et al.,
1990). In addition, the tumor necrosis factor-related re-
ceptor activator of NF-kB ligand (RANKL), which is dis-
played on the cell surface of preosteoblasts and osteo-
blasts, regulates the differentiation of preosteoclasts
by the interaction with the receptor activator of NF-kB
(RANK) (Dougall et al., 1999; Kong et al., 1999; Lacey
et al., 1998; Yasuda et al., 1998). Signaling by RANKL
can be modulated by the decoy receptor Osteoprote-
gerin (OPG), which binds RANKL and is secreted from
osteoblasts and several other cell types (Simonet et al.,
1997). The role of OPG in regulating osteoclast differen-
tiation and bone homeostasis was shown by targeted
gene inactivation of the Opg gene, which results in en-
hanced osteoclast formation and osteoporosis (Bucay
et al., 1998), and by the transgenic overexpression of
Opg, which results in osteopetrosis (Simonet et al.,
1997).
Several transcription factors have been shown to reg-
ulate the differentiation and function of osteoblasts and
osteoclasts. Differentiation of osteoblasts, which can be
monitored by the expression of markers such as alkaline
phosphatase, bone sialoprotein, and osteocalcin, is reg-
ulated by the transcription factors Runx2/Cbfa1 and Os-
terix. Runx2 is expressed at the onset of osteoblast dif-
ferentiation (Ducy et al., 1997), and targeted disruption
of this gene results in a complete absence of osteo-
blasts (Komori et al., 1997; Otto et al., 1997). Likewise,
the genetic inactivation of Osterix leads to an arrest of
osteoblast differentiation (Nakashima et al., 2002). In ad-
dition, the transcription factors ATF4 and TCF1 regulate
the function of osteoblasts, which includes the differen-
tiation of osteoclasts (Glass et al., 2005). This process
is also regulated by transcription factors that act in the
monocyte/myeloid lineage, such as Pu.1 (Tondravi et al.,
1997), NFATc, NF-kB, and the AP1 proteins c-fos and
c-jun, which function downstream of RANKL signaling
(Kenner et al., 2004; Takayanagi et al., 2002a, 2002b). Al-
though the role of the RANK-RANKL signaling pathway
in the osteoblast-mediated differentiation of osteoclasts
has been well established, our insight into the transcrip-
tional control mechanisms that operate upstream of this
signaling pathway is limited.
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family bind to DNA as homo- or heterodimers through a
zinc finger domain and a helix-loop-helix-like dimeriza-
tion domain (Dubois and Vincent, 2001). The founding
member of this family, EBF1, is expressed in B lympho-
cytes, adipocytes, and neuronal cells, and targeted in-
activation of the Ebf1 gene results in a block of early B
cell differentiation (Hagman et al., 1993; Lin and Gros-
schedl, 1995). Other family members, including EBF2
(O/E3) and EBF3 (O/E2), are expressed in adipocytes,
neurons, and several other cell types (Garel et al., 1997;
Malgaretti et al., 1997; Mella et al., 2004; Wang et al.,
2004). EBF proteins can act in a redundant manner,
but some functions have been attributed to specific
members of the family (Corradi et al., 2003; Wang et al.,
2004). Ebf2 is expressed in the embryonic central ner-
vous system (Malgaretti et al., 1997), and targeted gene
inactivation of Ebf2 has revealed an important function
in peripheral nerve morphogenesis, the migration of neu-
rons that produce gonadotropin-releasing hormone,
and projections of olfactory neurons (Corradi et al.,
2003; Wang et al., 2004). However, the role of EBF2 in
other developmental processes has not been studied.
In this study, we show that EBF2 is also expressed in os-
teoblastic progenitors and regulates osteoclast differ-
entiation by activating the gene encoding the RANK de-
coy receptor OPG.
Results
Expression of EBF2 in Osteoblastic Precursors
With the aim of examining the developmental expres-
sion pattern of EBF2 in more detail, we analyzed mice
that carry an in-frame insertion of the bacterial LacZ
gene immediately downstream of the translation initia-
tion site of the Ebf2 gene (Corradi et al., 2003). Whole-
mount staining for b-galactosidase activity at different
developmental stages showed that EBF2-lacZ is initially
expressed in the first and second branchial arches at E9,
in somites, specifically the forming sclerotomes, at E10
and E10.5, as well as in dorsal root ganglia at E12.5
(Figure S1; see the Supplemental Data available with
this article online). Cryosections of E16.5 embryos re-
vealed that EBF2 is expressed in bone-forming areas
and adipose tissue (Figure 1A). Moreover, EBF2 is ex-
pressed in specific neural tissues, as described previ-
ously (Corradi et al., 2003). A similar expression pattern
was observed in homozygous mutant embryos, indicat-
ing that the inactivation of the Ebf2 gene does not result
in a loss of EBF2-expressing cells (Figure 1B). In bone-
forming areas, EBF2 is expressed along the mesenchy-
mal condensations at E14.5 (Figure 1C), in the perichon-
drium, and in cells invading the cartilagenous structures
at E16.5 (Figure 1D). In situ hybridization of tibias of
E18.5 embryos to detect Ebf2 transcripts indicated that
individual Ebf2-expressing cells are scattered through-
out the trabecular/cancellous bone area of wild-type
mice, whereas no Ebf2 transcripts can be detected in
the corresponding areas of Ebf22/2 mice, which were
used as a negative control (Figures 1E and 1F).
Various cell types, including osteoblasts and macro-
phages, are attached to the bone. To characterize the
identity of the EBF2-expressing cells in more detail, we
isolated adherent and nonadherent bone marrow cellsfrom long bones of Ebf2+/2 neonatal mice, by using col-
lagenase and dispase, incubated the cells with anti-
CD45 antibody, and loaded the cells with the fluorogenic
b-galactosidase substrate FDG. In flow cytometry anal-
ysis, approximately 8% of the gated nonhematopoietic
cells were positive for LacZ activity, and all of the
CD45-positive hematopoietic cells were negative for
EBF2-lacZ (Figure 1G and data not shown). Real-time
RT-PCR analysis indicated that the EBF2-lacZ-express-
ing cells contain high levels of Runx2 and low levels of
Sox9 transcripts (Figure 1H). These cells also contained
low levels of transcripts of alkaline phosphatase and
bone sialoprotein, but no detectable transcripts of Os-
terix and osteocalcin. Moreover, EBF2-lacZ-expressing
cells contained transcripts of the chondrocyte marker
collagen2a1, but lacked transcripts of other markers of
chondrocytes (Figure S2A). We also analyzed the ex-
pression of EBF2 in sorted chondrocytes and in differen-
tiated osteoclasts. Neither chondrocytes nor osteoclasts
were found to expressEbf2 (Figure S2A; data not shown).
Finally, we examined the presence of EBF2-expressing
cells in calvarial bone preparations of E18.5 Ebf2+/2
mice by FDG loading and flow cytometry. We found
that 2%–3% of the cells were positive for EBF2-lacZ
(Figure S2B). Based on the expression of Runx2, the ab-
sence of osteocalcin transcripts, and the presence of
low levels of Sox9 and collagen2a1 transcripts, EBF2-
expressing cells appear to represent immature osteo-
blastic cells.
With the aim of further defining the expression of Ebf2
in osteoblastic cells, we performed in vitro differentia-
tion experiments with calvarial cells from newborn wild-
type mice (Bellows et al., 1990). In this experiment, we
placed calvarial cells of E18.5 wild-type mice into culture
for 3 days and thereafter differentiated the cells into ma-
ture osteoblasts by the addition of b-glycerophosphate
and ascorbic acid. Quantitative RT-PCR analysis of
three independent cultures indicated that the expres-
sion of Ebf2 is induced w5-fold within 2 days, but
declines after 4 days, when transcripts of Osterix and
osteocalcin are detected at high levels (Figure 2A).
Ebf3 showed a similar profile of expression, albeit at
a lower level, whereas transcripts of Ebf1 accumulate
in a pattern that resembles more that of Osterix. Taken
together, these data suggest that Ebf2 is expressed in
immature osteoblastic cells that may include osteo-
chondroprogenitor cells (Eames et al., 2004). Moreover,
EBF2 may be partially redundant with other members of
the EBF family of transcription factors.
Normal Bone Formation, but Low Bone Mass
and High Bone Resorption, in Ebf22/2 Mice
To examine the consequences of a loss of EBF2 function
on skeletal development, we performed alcian blue and
alizarin red staining of skeletons at E18.5. No obvious
differences in the morphology of bones and cartilages
were detected between wild-type and Ebf22/2 mice
(Figure 2B). Von Kossa staining and in situ hybridiza-
tions with probes to detect markers for osteoblasts
(bone sialoprotein, collagen1a1) or chondrocytes (colla-
gen2a1) did not reveal any significant changes in mutant
embryos (Figure 2C). Moreover, histomorphometric
analysis indicated that the cancellous bone area (B.Ar./
T.Ar.) in the distal femurs of E18.5 wild-type and Ebf22/2
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759Figure 1. Expression of EBF2 at Sites of Os-
teogenesis and in a Subset of Osteoblastic
Cells
(A and B) Staining for b-galactosidase in cryo-
sections of E16.5 (A) Ebf2+/2 and (B) Ebf22/2
embryos. EBF2-lacZ-positive cells can be
detected in adipose tissue and in cells sur-
rounding the cartilaginous structures of fu-
ture skeletal elements.
(C and D) Magnification of EBF2-lacZ stain-
ing in the area surrounding the future ribs
(as indicated in (A)) in (C) E14.5 Ebf2+/2 and
(D) E16.5 Ebf2+/2 embryos.
(E and F) In situ hybridization of the E18.5 tibia
to detectEbf2 transcripts in (E)Ebf2+/+ and (F)
Ebf22/2 embryos. Individual Ebf2-expressing
cells are attached to cancellous bone in
a scattered pattern (arrows).
(G)Cells isolated from boneof neonateEbf2+/2
animals are analyzed by flow cytometry to de-
tect EBF2-lacZ-expressing cells. Cells are
gated as CD45 negative, and the sorting gates
are indicated.
(H) Real-time RT-PCR analysis of the expres-
sion of Runx2, Sox9, Osterix (Osx), Alkaline
phosphatase (Ap), Bone sialoprotein (Bsp),
Osteocalcin (Ocn), Collagen1a1 (Col1a1),
andCollagen2a1 (Col2a1) in cells from neona-
tal bones of Ebf2+/2 mice. The cells were
sorted as positive or negative for the expres-
sion of EBF2-lacZ as indicated in (G). Error
bars represent the standard deviation of the
mean of three experiments.embryos is similar (Figure 2D). However, quantitative
RT-PCR assays to detect transcripts encoding regula-
tors of osteoblast differentiation or components of the
extracellular matrix indicated that the expression of
bone sialoprotein and osteocalcin is decreased mod-
estly, but reproducibly, in directly sorted Ebf22/2 osteo-
blastic cells, relative to Ebf2+/2 osteoblasts (Figure 2E).
Thus, the lack of EBF2 may result in a small defect in the
terminal differentiation of osteoblasts.To analyze the bones of older mice, we used mice at
3 weeks of age, when the dwarfism and impaired viability
of Ebf22/2mice is less severe than in adult mice (Corradi
et al., 2003). At 3 weeks of age, the size and weight of
the Ebf22/2mice are reduced by 22% and 43%, respec-
tively, relative to wild-type mice. X-ray analysis and his-
tology of the tibia at low resolution showed that tibial
length in EBF2-deficient mice is decreased byw19% rel-
ative to wild-type mice (Figures 3A and 3B). Von Kossa
Developmental Cell
760Figure 2. Expression of EbfGenes during Os-
teoblastic Differentiation and Embryonic
Bone Development in the Absence of EBF2
(A) Real-time RT-PCR analysis of the expres-
sion of Ebf1, Ebf2, and Ebf3 in calvarial cells
induced for osteoblastic differentiation for
the indicated time points. For comparison,
the induction of Runx2, Osterix (Osx), andOs-
teocalcin (Ocn) is shown. Error bars represent
the standard deviation of the mean of three
experiments.
(B) Alcian blue/alizarin red staining of carti-
lage and bone in the skeleton of E18.5 em-
bryos.
(C) Analysis of sections of E18.5 tibia bone
and cartilage by von Kossa staining and in
situ hybridizations to detect transcripts of
Bsp, Col1a1, and Col2a1.
(D) Histomorphometric analysis of von
Kossa-stained femurs of E18.5 embryos. Er-
ror bars represent the standard deviation of
the mean of four experiments.
(E) Cells isolated from cortical bones of E18.5
Ebf2+/2 and Ebf22/2 mice were sorted for the
expression of EBF2-lacZ (CD45 negative) and
were analyzed for the expression of Runx2,
Osx, alkaline phosphatase (Ap), Bsp, Ocn,
Osteopontin (Opn), Col1a1, and Col2a1 by
real-time RT-PCR. Error bars represent the
standard deviation of the mean of three ex-
periments.staining of femurs of wild-type and Ebf22/2 mice re-
vealed a cancellous and cortical bone osteopenia in the
mutant mice (Figure 3C). The cortical thickness of the fe-
mur midshaft, measured by histomorphometry, was re-
duced by 65% in mutant mice (1366 17 mm versus 616
8 mm, wild-type versus Ebf22/2; n = 4–5). High-power
micrographs of cortical bone in the midshaft region
showed areas of osteoclastic endocortical bone resorp-
tion in mutant, but not wild-type, mice (Figure 3C). To
quantify the effects of cortical thinning on bone bio-
mechanics, we performed three-point bending tests of
femurs from wild-type and Ebf22/2 mice. We found
an w3-fold decrease in ultimate force in Ebf22/2 mice
(Figure 3D).
Von Kossa staining also indicated that the cancellous
bone area (B.Ar/T.Ar) and the width of the growth plate
of Ebf22/2 mice are reduced, whereas the number ofadipocytes is increased, as shown for the proximal tibial
metaphysis (Figure 3E). Osteoblasts could be detected
in normal numbers in histological sections (data not
shown), and the rate of cancellous bone formation, as
measured by calcein fluorochrome labeling, showed no
significant difference between wild-type and Ebf22/2
mice (0.996 0.22 mm2/mm/day in wild-type versus 1.186
0.18 mm2/mm/day in Ebf22/2mice; n = 4–5). Furthermore,
quantitative RT-PCR analysis of the expression of oste-
oblastic marker genes in cells isolated from the tibia of
3-week-old wild-type and EBF2-deficient mice did not
reveal any significant differences (Figure S2C). Finally,
van Gieson staining of femurs showed a similar density
and direction of collagen fibers in Ebf2+/+ and Ebf22/2
mice (Figures S2D and S2E). However, we detected an
increase in the number of TRAP-positive osteoclasts
in EBF2-deficient mice (Figure 3G). Quantification of
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761Figure 3. Osteopenia and Increased Osteo-
clastic Bone Resorption in 3-Week-Old
Ebf22/2 Mice
(A) X-ray analysis of Ebf2+/+ (+/+) and Ebf22/2
(2/2) mice indicates decreased mineral den-
sity in the mutant mice.
(B) Haematoxylin/Eosin staining of the tibia
from Ebf2+/+ and Ebf22/2 mice shows a de-
creased bone length (19%) in the mutant mice.
(C) Von Kossa staining shows reduced bone
matrix in femurs of EBF2-deficient mice
(left). Higher magnification of the cortical
bone area reveals a reduction in thickness
by 65% and the presence of osteoclasts
(arrowheads) adjacent to cortical bone (right).
(D) Biomechanic testing by three-point bend-
ing of femurs; n = 3–4.
(E) Von Kossa staining of sections of the
proximal tibia indicates a pronounced can-
cellous bone osteopenia in the metaphysis of
Ebf22/2 mice relative to wild-type mice. Mu-
tant mice have a reduction of cortical bone
thickness, and they show an increase in the
number of bone marrow fat cells (white).
(F) Bone histomorphometry reveals a 49% re-
duction in the tibial cancellous bone area
(B.Ar/T.Ar., %) in Ebf22/2 mice (top). Periph-
eral quantitative computed tomography
(pQCT) shows a decrease in the total bone
mineral density (BMD, mg/cm3) of the distal
femoral metaphysis by 40% in Ebf22/2 mice
(bottom). n = 4–5.
(G) Staining to detect tartrate-resistant acid
phosphatase (TRAP)-positive osteoclasts in-
dicates that Ebf22/2 mice have an increased
number of differentiated osteoclasts (stained
in red) covering the bone surface.
(H) Osteoclast perimeter (Oc.Pm/B.Pm, %) is
increased by 47% in Ebf22/2 mice relative to
wild-type mice (top). Urinary excretion of the
bone resorption marker deoxypyridinoline
(DPD) is elevated in Ebf22/2 mice (bottom).
DPD excretion is corrected for creatinine ex-
cretion, and it is expressed as a percentage
of wild-type control. n = 4–5.
*p < 0.05 as compared with wild-type by
t test. Error bars in (D), (F), and (H) represent
the standard deviation of the mean of the
analysis of four to five mice.these defects by bone histomorphometry indicated that
the trabecular bone area of the tibia is reduced by 49%
relative to wild-type mice (Figure 3F). These findings
were confirmed by peripheral quantitative computer to-
mography (pQCT), showing that the bone mineral den-
sity (BMD) of both the distal metaphysis and shaft of the
femur of Ebf22/2 mice is diminished by 40% (Figure 3F;
Table S1). Finally, the osteoclast perimeter (Oc.Pm/
B.Pm), a measurement of the surface of bone covered by
osteoclasts, was increased by 47%, and the urinary ex-
cretion of the collagen degradation product deoxypyridi-
noline (DPD), a whole body marker for bone resorption,
was elevated by 50% in the mutant mice (Figure 3H).
Taken together, these data indicate that the osteopenia
in EBF2-deficient mice, which is more pronounced
than can be accounted for by the dwarfism, is due to
an increased bone resorption and enhanced osteoclas-
togenesis.Deregulated Expression of Osteoprotegerin
and Rankl in Ebf22/2 Osteoblasts
The observed increase in the number of osteoclasts in
EBF2-deficient mice prompted us to examine the ex-
pression of components of the RANK-RANKL signaling
pathway that regulate communication between osteo-
blasts and osteoclasts. In a first step, we examined the
expression of the Rankl and Opg genes by immunohis-
tochemistry on tibia bones from Ebf2+/+ and Ebf22/2
E18.5 embryos (Figures 4A and 4B). Expression of OPG
and RANKL proteins could be detected in cells adjacent
to trabecular bone. Relative to wild-type mice, however,
the expression of OPG appeared weaker, and that of
RANKL appeared stronger, in Ebf22/2 mice. To confirm
the putative changes in the expression of these compo-
nents of the RANK-RANKL signaling pathway, we puri-
fied osteoblasts from the calvariae of heterozygous
and homozygous mutant newborn mice by sorting for
Developmental Cell
762Figure 4. Deregulated Expression of Osteo-
protegerin and Rankl in Ebf22/2 Osteoblasts
and Osteoblast-Dependent Bone Resorption
Defect
(A and B) Immunohistochemical staining for
(A) Osteoprotegerin (OPG) and (B) RANKL in
sections of tibias of Ebf2+/+ and Ebf22/2
mice. Topro3 was used for the staining of
DNA.
(C) RT-PCR analysis to detect transcripts of
Opg, Rankl, Runx2, and Pparg in Ebf2+/2
and Ebf22/2 calvarial cells that have been iso-
lated under standard conditions for osteo-
blasts, expanded in culture (two passages),
and sorted for the expression of EBF2-lacZ.
(D) Real-time RT-PCR analysis of Opg and
Rankl mRNA in sorted osteoblasts without
prior in vitro culture. Error bars represent
the standard deviation of the mean of three
experiments.
(E) Determination of serum levels of OPG
from Ebf2+/+, Ebf2+/2, and Ebf22/2 mice by
ELISA reveals a reduction of OPG in the ab-
sence of EBF2 by 40%. Error bars represent
the standard deviation of the mean of four ex-
periments.
(F) Enhanced osteoclast differentiation on
Ebf22/2 osteoblasts in vitro is reversed by re-
combinant OPG. EBF2-lacZ-positive osteo-
blastic cells from Ebf2+/2 and Ebf22/2 mice
were sorted by flow cytometry and were co-
cultured with primed bone marrow cells
(BMs) from Ebf2+/+ or Ebf22/2 mice as indi-
cated. Recombinant OPG protein was added
at three different concentrations (5, 25, and
50 ng/ml) into the osteoblast-BM coculture,
and the appearance of TRAP-positive cells
was measured after 5 days of coculture. Error
bars represent the standard deviation of the
mean of three experiments.b-galactosidase activity, expanded the cells in culture,
and analyzed the expression of putative EBF2 target
genes by RT-PCR. In EBF2-deficient osteoblasts, the
number of Opg transcripts was markedly reduced,
whereas the number of Rankl transcripts was increased
(Figure 4C). No significant changes in the expression of
Runx2 and Pparg were observed (Figure 4C). With the
aim of quantifying these effects and extending the ob-
servations to cells that have not been cultured in vitro,
we performed quantitative RT-PCR to detect transcripts
in heterozygous and homozygous EBF2-expressing os-
teoblastic cells that have been sorted directly after iso-
lation. In homozygous mutant cells, the expression of
Opg was decreased by a factor of 14, and the expres-
sion of Rankl was increased by a factor of 5 (Figure 4D).Osteoblast-Autonomous Defect of Osteoclast
Differentiation in Ebf22/2 Mice
The increase in osteoclast numbers in the bones of
EBF2-deficient mice and the downregulation of Opg ex-
pression in Ebf22/2 osteoblasts raised questions as to
whether these defects result in a decrease in the serum
levels of OPG and whether the defects are osteoblast
autonomous. Although OPG is expressed by a variety of
cell types, the levels of OPG in the serum of 3-week-old
Ebf22/2mice were reduced by 41% relative to wild-type
mice (Figure 4E). We also examined whether the defects
in osteoclastogenesis can be recapitulated in vitro and
overcome by the addition of recombinant OPG. Toward
this end, we incubated wild-type bone marrow cells
with macrophage colony-stimulating factor (M-CSF) to
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cells on osteoblastic cells from heterozygous and ho-
mozygous mutant mice that had been sorted for the ex-
pression of EBF2-lacZ. Osteoblast-mediated differenti-
ation of the bone marrow cells into osteoclasts was
monitored by TRAP staining. The number of osteoclasts
in the coculture with Ebf22/2 osteoblasts was 57%
higher than in the coculture with Ebf2+/2 osteoblasts
(Figure 4F). As a control, no difference in the generation
of osteoclasts was observed with EBF2-deficient bone
marrow cells compared to wild-type bone marrow cells.
If the increase in the differentiation of osteoclasts is de-
pendent on the decrease of OPG expression in Ebf22/2
osteoblasts, it should be possible to reverse the defect
by the addition of exogenous OPG protein. Therefore,
we added increasing amounts of recombinant OPG to
the bone marrow cells being cultured with Ebf2+/2 or
Ebf22/2 osteoblasts. In both cocultures, the numbers
of TRAP-positive osteoclasts were reduced in a dose-
dependent manner, although more exogenous OPG is
needed in the Ebf22/2 cultures to achieve a similar block
in osteoclast differentiation as in the Ebf2+/2 cultures.
Therefore, the enhanced differentiation of osteoclasts
on EBF2-deficient osteoblasts appears to be linked to
the decrease in the expression of OPG. Moreover, these
data indicate that the osteoclast defect in Ebf22/2 mice
is osteoblast autonomous.
Osteoprotegerin Is a Direct Target for EBF2
To examine whether Opg or Rankl are direct or indirect
targets of EBF2, we searched for binding sites of EBF
proteins in the promoter of these genes. No binding sites
could be identified in the murine Rankl promoter (Kita-
zawa et al., 1999). In the promoter of the human OPG
gene, which has been functionally characterized (Thiru-
navukkarasu et al., 2000), four potential EBF binding sites
were identified in a region 1.5 kb upstream of the tran-
scription start site. Two of these sites at2993 and2184
were confirmed as bona fide binding sites in an electro-
phoretic mobility shift assay (Figures 5A and 5B). For
this experiment, we used the DNA binding and dimeriza-
tion domain of EBF1, which can be purified in recombi-
nant and soluble form and has the same DNA binding
specificity as EBF2 (Hagman et al., 1993; Malgaretti
et al., 1997). The efficiency of binding to the 2184 site
of theOPG promoter was similar to that of the high-affin-
ity site in themb1promoter (Travis et al., 1993). The spec-
ificity of DNA binding was confirmed by the lack of EBF
binding to a mutant (mut) site. Binding of EBF to the sec-
ond site at 2993 of OPG was observed at an w3-fold
lower efficiency (Figure 5B). We also confirmed the bind-
ing of EBF2 to the site at2184 by using nuclear extracts
from 293 cells that express EBF2, but not EBF1 (data not
shown), and by competing with specific or nonspecific
oligonucleotides (Figure S2F).
Previous analysis of the OPG promoter indicated that
truncations between 5.9 kb and 0.4 kb have modest
effects on the basal promoter activity and on the respon-
siveness of the promoter to TGFb signals (Thirunavuk-
karasu et al., 2001). Therefore, we examined the func-
tional importance of EBF2 in the context of a 700 bp
promoter fragment containing the wild-type or a mutated
EBF binding site at2184. Transient transfection ofOPG-
luciferase gene constructs (OPG-luc) into HeLa cells,alone or together with an expression plasmid for EBF2,
indicated that EBF2 augments the activity of the wild-
type OPG promoter fragment by a factor of six, whereas
the point-mutated promoter was stimulated only 2-fold
(Figure 5C). Based on the presence of a Runx2 binding
site at2303 (Thirunavukkarasu et al., 2000), we also co-
transfected theOPG-luc reporter construct with a Runx2
expression plasmid. No significant activation was ob-
served, consistent with the lack of an effect of mutation
of the Runx2 binding site in an osteosarcoma cell line
(Thirunavukkarasu et al., 2001). However, Runx2 could
potentiate the EBF2-mediated activation of the OPG-
luc reporter by a factor of two, suggesting that these
transcription factors may modestly cooperate in the reg-
ulation OPG (Figure 5C). Moreover, transfection of the
wild-type and mutated OPG-luc reporters into C2C12
cells, which express low levels of EBF2, indicate that
the mutation of the EBF2 binding site decreases reporter
gene expression by a factor of two (Figure 5D; data not
shown).
Recently, the OPG gene was shown to be directly reg-
ulated by LEF1 and b-catenin in response to Wnt signal-
ing (Glass et al., 2005). Therefore, we examined whether
EBF2 cooperates with the Wnt signaling pathway in the
regulation of OPG. Toward this end, we transfected
HeLa cells with the OPG-luc reporter, together with the
expression plasmid for EBF2 alone, or in combination
with LEF1 and b-catenin (Figure 5E). The activity of the
OPG promoter was augmented modestly by either EBF2
or LEF1/b-catenin alone, but it was markedly increased
by the combination of EBF2 and LEF1/b-catenin.
To further examine the role of EBF2, Runx2, and LEF1/
b-catenin in the regulation of the endogenousOPGgene,
we transfected the EBF2 or Runx2 expression plasmids,
alone or in combination, into HeLa cells and analyzed the
expression of OPG by quantitative RT-PCR. Both EBF2
and LEF1/b-catenin could induce the expression of en-
dogenous OPG, but the activation was more efficient
in cells that have been transfected with both EBF2 and
LEF1/b-catenin expression plasmids (Figure 5F). Taken
together, these data indicate that EBF2 directly regu-
lates the expression of OPG and synergizes strongly
with components of the Wnt signaling pathway.
Discussion
Our study identifies EBF2 as a regulator of osteoclasto-
genesis and bone homeostasis that acts upstream of
RANKL signaling. The role of EBF2 in the regulation of
OPG is based on multiple lines of evidence. First, the ex-
pression of Opg in sorted EBF2-deficient osteoblastic
cells is reduced 14-fold. Moreover, the expression of
EBF2 in HeLa cells activates theOPG promoter via bind-
ing to specific sites in the promoter region, and EBF2 in-
duces the expression of the endogenous OPG gene.
Opg is not only expressed in osteoblastic cells, but it is
also expressed in several other cell types, including cells
that are negative for the expression of EBF2 (Simonet
et al., 1997). Therefore, it is likely that other transcription
factors also participate in the regulation of the expres-
sion of OPG. Runx2, a key regulator of the osteoblast
cell lineage, has been shown to regulate the promoter
of OPG in transient transfection experiments (Thiru-
navukkarasu et al., 2000). However, Opg is efficiently
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(A) Schematic representation of binding sites
for EBF, LEF/TCF, and Runx2 proteins in the
human OPG promoter. Sequences and posi-
tions of wild-type (wt) and mutated (mut)
EBF binding sites relative to the transcrip-
tional start site are indicated. The mutations
are shown in lower case letters.
(B)Electrophoreticmobility shift assay (EMSA)
to detect binding of the recombinant DNA
binding and dimerization domain of EBF1
(30, 100, and 300 ng) to 32P-labeled oligonu-
cleotides encompassing the EBF binding
sites in the OPG or mb1 promoters (Travis
et al., 1993).
(C) HeLa cells were transiently transfected
with 0.3 mg luciferase reporter (OPG-luc)
alone, or together with 0.8mg expression plas-
mids for EBF2 or 0.8 mg Runx2, as indicated.
The same mutation as in the EMSA (see [A]
and [B]) was used in the luciferase construct
as a control (OPG-mut-luc). The levels of lucif-
erase activity were normalized to the expres-
sion of a cytomegalovirus b-galactosidase
reporter plasmid. In all reporter assays, the
values represent duplicates of representative
transfections.
(D) C2C12 cells, which express Ebf2, were
transfected with the OPG-luc or OPG-mut-
luc reporter plasmids as described above.
(E) HeLa cells were transiently transfected
with 0.1 mg OPG-luc reporter alone, or to-
gether with expression plasmids for EBF2
(0.4 mg) or LEF-1 (50 ng) and b-catenin
(0.5 mg), as indicated. As a positive control,
a Lef7-luciferase reporter, containing multi-
merized LEF1 binding sites, was used. The
levels of luciferase activity were normalized
for b-galactosidase activity. In the reporter
assays (C–E), error bars represent the devia-
tion from the mean of duplicate transfections.
(F) HeLa cells were transiently transfected
with expression plasmids for Runx2, EBF2,
LEF1, or b-catenin alone, or in combination,
as indicated. The expression of the endoge-
nous OPG gene was measured by real-time
PCR. Since OPG transcripts could not be de-
tected in mock-transfected cells, the lowest
value (Runx2 transfection) was set to 1. Error
bars represent the standard deviation of the
mean of three experiments.expressed in a Runx22/2 calvaria-derived cell line, and
forced expression of Runx2 via adenoviral transduction
of these cell results in suppression ofOpg and activation
of Rankl expression (Enomoto et al., 2003). In addition, it
has been shown that Runx2 is not essential for vitamin
D-regulated expression ofRankl andOpg in osteoblastic
cells (Notoya et al., 2004). Moreover, our transfection ex-
periments in HeLa cells indicate that Runx2 has only
a modest effect on the activity of theOPG promoter con-
struct, although Runx2 could augment the expression of
the endogenous OPG gene. Thus, the effects of Runx2
on the expression of OPG are likely to be indirect.
Another member of the Runx family of transcription
factors, Runx1, has been shown to cooperate with EBF1
in the lymphocyte-specific regulation of the mb1 gene
(Maier et al., 2004). In this context, EBF1 and Runx1
bind to adjacent binding sites in the mb1 promoter and
mediate DNA hypomethylation and changes in chroma-
tin structure. Therefore, either or both of these proteinsappear to act as ‘‘pioneer factors’’ in the transcriptional
activation of target genes.
Recently, Karsenty and coworkers have found that
the Wnt signaling pathway regulates osteoblast expres-
sion of Opg (Glass et al., 2005). Induced stabilization of
b-catenin in osteoblasts was found to result in a higher
bone mass, whereas conditional deletion of b-catenin
resulted in osteopenia. Moreover, expression of Opg
was found to be upregulated in osteoblasts containing
stabilized b-catenin and downregulated in osteoblasts
from which b-catenin has been deleted (Glass et al.,
2005). This study also showed that the Wnt-responsive
transcription factor TCF1 binds directly to three sites
in a 3.6 kb promoter fragment of the Opg gene in vitro
and in vivo. Consistent with our observations, no bind-
ing of Runx2 to the Opg promoter was detected in chro-
matin immunoprecipitation experiments in vivo (Glass
et al., 2005). In contrast to the weak cooperation of EBF2
and Runx2 in the regulation of the Opg gene, we found
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of the LEF1/TCF family of Wnt-responsive transcription
factors. Both EBF2 and LEF1/TCF proteins are ex-
pressed in specific cell types, and the functional synergy
may contribute to a more restricted pattern of Wnt-
regulated expression of Opg.
In addition to the effects of Wnt signaling in differen-
tiated osteoblasts that includes the regulation of Opg,
b-catenin also has an effect in osteoblast precursors,
because the conditional deletion of b-catenin in mesen-
chymal progenitor cells prevents differentiation into os-
teoblasts (Hill et al., 2005). Therefore, the functional syn-
ergy between EBF2 and LEF1 may operate only at
specific target genes that include Opg.
EBF2 may also be involved in multiple aspects of os-
teoblast function and/or differentiation. Although EBF2
regulates the expression ofOpg in osteoblastic cells, the
targeted gene inactivation of Ebf2 has no major effect on
the generation of osteoblasts or on the rate of bone for-
mation, suggesting that EBF2 is dispensable for osteo-
blast differentiation and function. However, EBF2 may
act in a redundant manner with other members of the
EBF family of transcription factors in regulating osteo-
blast differentiation. Consistent with this possibility,
EBF1 and EBF3 transcripts can be detected in EBF2-
expressing osteoblastic cells. Interestingly, the tempo-
ral patterns of the expression of specific members of
the EBF family of transcription factors differ during oste-
oblast differentiation. In an in vitro model for osteoblast
differentiation (Bellows et al., 1990), abundant expres-
sion of Ebf2 is already detected at 2 days of culture, but
ceases after 1 week of culture. In contrast, the expres-
sion of Ebf1, together with Osterix, peaks after 1 week
of culture. The combined inactivation of both Ebf1 and
Ebf2 should shed light on the potential redundancy of
EBF proteins in osteoblast differentiation.
To date, our insight into the regulation of the activity of
EBF proteins is still limited. The DNA binding ability of
EBF1 has been found to be inhibited by Notch signaling
(Smith et al., 2005), raising the possibility that a similar
regulation may modulate the activity of EBF2. Thus, mul-
tiple signaling pathways may regulate the differentiation
of osteoclasts via osteoblast-specific transcription fac-
tors that act on promoters of genes involved in RANK-
RANKL signaling. In addition, signaling by interferon-b,
which is activated by c-fos, antagonizes the RANK-
mediated regulation of c-fos in osteoclasts, generating a
regulatory feedback loop (Takayanagi et al., 2002b). An
insight into the regulatory network of transcription fac-
tors that regulates RANK-RANKL signaling will be impor-
tant for the detailed understanding of the homeostatic
interactions between osteoblasts and osteoclasts.
Experimental Procedures
PCR, RT-PCR, and Real-Time PCR
Genotyping of Ebf2 mutant animals was performed as described
(Corradi et al., 2003). RT-PCR was carried out according to standard
protocols, by using Superscript II reverse transcriptase (Invitrogen)
and the oligo-dT primer (Roche). Real-time PCR was performed with
SYBR GREEN PCR master mix (Applied Biosystems) and the ABI
PRISM 7000 sequence detection system (Applied Biosystems).
The sequences for primer pairs used in PCR reactions are given in
Supplemental Experimental Procedures. Three independent mea-
surements were performed for each PCR analysis.Isolation and Cultivation of Cells
Preparation of osteoblastic cells from neonate bones was per-
formed as described (Bakker and Klein-Nulend, 2003). Hindlegs
from animals of the respective genotypes were isolated, and muscle
and other tissue were removed. The bones were cleaned quickly in
alcohol and PBS and were shaken for 15 min at 37ºC in aMEM me-
dium containing 0.1% collagenase (Sigma) and 0.2% neutral dis-
pase II (Roche). This was repeated once, and the first two fractions
were discarded. Subsequently, bones were incubated in the de-
scribed medium three more times. These fractions were collected,
and cells isolated from the fractions were immediately subjected
to FDG loading and FACS analysis. Osteoblasts were also isolated
from calvariae of day 2–5 newborn animals, and osteoblast-osteo-
clast coculture experiments were performed as described (Jochum
et al., 2000). A total of 105 osteoblasts/well (24-well plate) were
sorted as lacZ+ from Ebf2+/2 and Ebf22/2 mice and were allowed
to attach to the plastic dish overnight. Osteoblasts were incubated
with 106 bone marrow cells per well. These bone marrow cells had
been primed as osteoclast progenitors by overnight incubation with
5 ng/ml M-CSF. The incubation medium for coculture was aMEM,
supplemented with 10% FCS, 1028 M 1a,25(OH)2D3-dihydroxy-
vitamin D3, and 1027 M dexamethasone. Osteoclast differentiation
was measured by TRAP staining after 5 days. Chondrocytes used
in real-time PCR were sorted cells from Col2-GFP transgenic mice
(kind gift from Christine Hartmann; Grant et al., 2000). In vitro dif-
ferentiation of osteoblasts was carried out by culturing freshly iso-
lated calvarial cells in aMEM medium as described above. After
3 days, osteoblastic differentiation was induced by adding 100 mM
b-glycerophosphate and 50 ng/ml ascorbic acid to the medium.
b-Galactosidase Detection and Flow Cytometry
For sorting of EBF2-lacZ-positive cells, osteoblastic cells were
loaded with fluorescein digalactoside (FDG; Molecular Probes)
through hypotonic shock (75 s at 37ºC) as described by the manu-
facturer. For each sample, propidium iodide (Sigma) was used to
gate out dead cells.
In Situ Hybridization and Immunohistochemistry
In situ hybridization was performed as described (Malgaretti et al.,
1997). The riboprobe for Ebf2 was generated from the full-length
cDNA (Malgaretti et al., 1997). For immunohistochemistry, compara-
ble sections were fixed in 4% PFA for 15 min, washed in TBST 0.1%
Triton X-100, blocked for 2 hr at room temperature in 10% goat
serum, and incubated with primary antibody overnight at 4ºC. As
first antibody, either biotinylated anti-mouse OPG (R&D Systems,
BAF459) or biotinylated anti-mouse RANKL (R&D Systems,
BAF462) was used at a concentration of 1:20. After washing, strep-
tavidin-AlexaFluor546 conjugate was used to detect primary anti-
body (2 mg/ml; 1:500). For nuclear staining, specimens were treated
with TOPRO3 (Molecular Probes).
Bone Histology and Histomorphometry
Processing of bone specimens and cancellous bone histomorphom-
etry in the proximal tibial metaphysis were performed as described
(Erben, 1997). The area within 0.25 mm from the growth plate was
excluded from the measurements in 3-week-old mice. In distal
femurs from E18.5 embryos, the cancellous bone, including calcified
cartilage, from the growth cartilage-metaphyseal junction until mid-
diaphysis was measured in von Kossa-stained paraffin sections.
Bone Mineral Density Measurements and Radiography
Bone mineral density (BMD) of the left femur was measured by
peripheral quantitative computed tomography (pQCT) by using a
XCT Research M+ pQCT machine (Stratec Medizintechnik). One
slice (0.2 mm thick) in the mid-diaphysis of the femur and three slices
in the distal femoral metaphysis located 1.5, 2, and 2.5 mm proximal
to the articular surface of the knee joint were measured. BMD values
of the distal femoral metaphysis were calculated as the mean over
three slices. A voxel size of 0.070 mm and a threshold of 600 mg/cm3
were used for calculation of cortical BMD.
Bone Biomechanics
Femur bones were prepared from 3-week-old mice and were loaded
to failure by three-point bending tests, by using a Zwick Z020/TN2A
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tance between the lower supports was 5 mm, and the crosshead
speed during testing was 0.2 mm/s. From the force-displacement
data, ultimate force (Fmax, N) was calculated.
ELISA
Serum from 3-week-old sex-matched animals (n = 4) was isolated,
and OPG levels were measured by using the Quantikine mouse
OPG ELISA kit (R&D systems).
EMSA
EBF protein (Hagman et al., 1993) was generated as a HIS tag fusion
protein in E. coli, and purification was performed by using the HIS
tag according to standard procedures. A total of 30, 100, or 300 ng
purified EBF, or 3 or 10 mg nuclear extract from 293T cells, were
mixed with 10,000 cpm 32P-labeled probe and 100 ng/ml dI/dC in a
20 ml reaction mix as previously described (Hagman et al., 1993).
For a list of oligonucleotides, see Supplemental Experimental Proce-
dures. Reactions were incubated at 20ºC for 30 min and then run on
a 6% nondenaturating acrylamide gel.
Gene Constructs, Transfection, and Luciferase Assay
The 1.3 kb fragment of the OPG promoter (OPG-luc) was cloned by
PCR amplification from genomic DNA (for primers, see Supplemen-
tal Experimental Procedures) and were subcloned into pGL3-basic
(Promega). The truncation of the OPG promoter (OPG-luc; 2706
to +44) was carried out by cutting OPG-luc with NheI and ApaI and
religation. The mutation of EBF binding site f1 was performed by
site-directed mutagenesis (for primers, see Supplemental Experi-
mental Procedures). HeLa cells were transfected with 2 mg plasmid
DNA and 10 mg salmon sperm DNA by the calcium phosphate
method. Cells were harvested 36–48 hr posttransfection in 100 ml re-
porter lysis buffer. Luciferase assays were conducted according to
the manufacturer’s instructions (Promega), and b-galactosidase as-
says were performed as described (Starr et al., 1996).
Supplemental Data
Supplemental Data including the embryonic expression pattern
of EBF2, peripheral quantitative computed tomography (pQCT) of
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